Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Halozyme Therapeutics

NASDAQ: HALO ↗$110.42 USD
#Drug Delivery#Oncology#Immunology

Biopharmaceutical company whose ENHANZE recombinant human hyaluronidase platform enables subcutaneous delivery of partnered biologics; also markets oncology and drug-delivery products.

Company Info

Sector:Biotechnology
Headquarters:San Diego, CA, USA
Founded:1998
Website:halozyme.com/

Clinical Development Pipeline

ENHANZE (rHuPH20)

Target: Recombinant human hyaluronidase
Subcutaneous co-formulation platform for partnered biologics
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Darzalex Faspro (with Janssen)

Target: CD38
Multiple myeloma
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Vyvgart Hytrulo (with argenx)

Target: FcRn
Generalized myasthenia gravis; chronic inflammatory demyelinating polyneuropathy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Helen Torley

President and Chief Executive Officer

Careers & Job Openings

See all open roles

All
San Diego, CA
Apply Now →